Carelane sets new standards for clinical research with AI-driven, end-to-end platform
News Article
- Carelane increases speed and efficiency, and improves the quality of clinical trials with an AI-powered clinical research hub
- Significant time and cost savings: cost reduction of up to 80 percent
- Seed funding of EUR 2.6 million led by Vorwerk Ventures
As clinical studies are always increasing in complexity, research institutions’ software solutions remain fragmented and outdated. Carelane has developed an end-to-end platform that integrates all phases of a study, from protocol development to data analysis. Their innovative approach combines the latest AI technology with a structured digital protocol based on FHIR standards. More than 130 research sites across six continents already rely on Carelane’s software solution. “We’ve engineered a cutting-edge platform that meets the demands of intricate clinical studies and increases efficiency through AI and automation. Workflows are simplified, clinical trials can be completed faster, and the overall quality is elevated,” explains CEO Yannick Boerner.
The research tool of tomorrow
More efficient, cheaper, and higher-quality clinical trials – Carelane achieves this via:
- End-to-end platform: Carelane covers all steps from protocol development to evaluation, with seamless integration promoting efficient collaboration. This eliminates traditional bottlenecks by linking all stakeholders to a shared, real-time infrastructure.
- Resource efficiency: Because there are fewer manual processes, the burden on research sites is eased, leading to cost savings of up to 80 percent. And because of AI-driven assistance and automation, research teams save time on study setup, site onboarding and participant enrolment.
- Increased data quality: Standardized data collection, real-time monitoring with built in AI-agents, and automated validation ensure reliable data and reduce protocol amendments.
A new era for study planning and execution
Carelane supports research teams from the earliest planning phases. The platform’s integrated AI-agents assist in decision-making, planning, and automating complex processes. The structured digital protocol based on FHIR standards ensures improved data quality. It guarantees synchronization with downstream systems and enables source data capture through the ingestion of electronic health records (EHRs). Researchers and study teams can now seamlessly move from creating their digitized protocol to configuring and deploying integrated modules, including EDC, eConsent, eCOA, EHR/EMR integrations, tokenization, and participant management.
Future-proof research – collaborative and integrated
All stakeholders – from sponsors to CROs to research sites – should be able to collaborate in real-time – Carelane makes this a reality. Stakeholders can now manage processes more effectively, and eliminate people silos and data silos. The tool brings all stakeholders together in a single digital infrastructure for the first time. Instead of separate tools, users can now rely on just one platform for medical writing, clinical strategy, operations, and data management. Carelane’s collaborative platform revolutionizes clinical research – a vision that found broad support in the investor community.
Successful seed funding completed
After a successful pre-seed phase, Carelane secured 2.6 million euros in April 2025 during a seed funding round led by Vorwerk Ventures, with additional participation from High-Tech Gründerfonds (HTGF) and private investors. “Carelane is revolutionizing how clinical research is done. We are impressed by how quickly they have gained traction. This rapid adoption shows the value that their AI-driven, end-to-end platform brings to a sector which is hungry for more efficient and higher-quality research. We are excited to support the company in its course of growth,” says Sascha Günther, partner of Vorwerk Ventures. The capital will be used to expand sales and customer support, scale technological infrastructure, and drive the further development of AI functions.
About Carelane
Carelane is re-imagining how clinical research gets done – with AI-powered technology that breaks down both data silos and people silos. Carelane is the AI-native clinical-research hub combining protocol authoring, EDC, eCOA, eConsent, participant management, tokenization, data analysis, document management and EMR/EHR connectivity in a single collaborative workspace. Every stakeholder—Medical Writing, Clinical Strategy, Clinical Operations, Data Management, Regulatory, Market Access, Sites, CROs, Sponsors and participants—works from a single source of truth without bouncing between disconnected point solutions.
For more information: www.carelane.io
About HTGF – High-Tech Gründerfonds
HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing startups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports startups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Since its inception in 2005, HTGF has financed more than 780 startups and achieved almost 200 successful exits. HTGF has a fund volume of over 2 billion euros.
Fund investors in the public-private partnership include the Federal Ministry for Economic Affairs and Energy, KfW Capital as well as 45 companies and family offices. For more information, please visit HTGF.de or follow us on LinkedIn.
Media contact
High-Tech Gründerfonds Management GmbH
Tobias Jacob, Senior Marketing & Communications Manager
T.: +49 228 – 82300 – 121
t.jacob@htgf.de
Do you want to
learn more?
I am your contact
for all press inquiries:
Tobias Jacob
More News

kiutra secures €13M to eliminate bottlenecks from quantum supply chains with helium-3-free cooling

Factor2 Energy Raises US$9.1M to Unlock Scalable Geothermal Power from Geologically Stored CO₂

Biotech company Mevaldi successfully closes funding round with HTGF and ICIG Ventures to scale up breakthrough technology for green chemistry
